LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

NVS

122.16

-0.62%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

NVS

122.16

-0.62%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

NVS

122.16

-0.62%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

NVS

122.16

-0.62%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

NVS

122.16

-0.62%↓

Search

Bio-Techne Corp

Gesloten

SectorGezondheidszorg

51.43 -0.46

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

50.92

Max

53.64

Belangrijke statistieken

By Trading Economics

Inkomsten

-40M

-18M

Verkoop

783K

317M

K/W

Sectorgemiddelde

117.63

35.664

EPS

0.53

Dividendrendement

0.59

Winstmarge

-5.577

Werknemers

3,100

EBITDA

-61M

6.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.59%

3.12%

Volgende Winsten

29 okt 2025

Volgende dividenddatum

21 nov 2025

Volgende Ex Dividend datum

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-473M

8.4B

Vorige openingsprijs

51.89

Vorige sluitingsprijs

51.43

Nieuwssentiment

By Acuity

27%

73%

82 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Bio-Techne Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 sep 2025, 17:03 UTC

Belangrijke Marktbewegers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sep 2025, 16:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

GD Culture Shares Drop After Deal for Pallas Capital

16 sep 2025, 16:11 UTC

Belangrijke Marktbewegers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sep 2025, 23:40 UTC

Marktinformatie

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sep 2025, 23:34 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sep 2025, 23:20 UTC

Marktinformatie

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sep 2025, 21:10 UTC

Acquisities, Fusies, Overnames

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sep 2025, 20:51 UTC

Marktinformatie

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 20:25 UTC

Winsten

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sep 2025, 20:24 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sep 2025, 19:19 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sep 2025, 18:52 UTC

Marktinformatie

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sep 2025, 18:40 UTC

Acquisities, Fusies, Overnames

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sep 2025, 18:38 UTC

Marktinformatie

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sep 2025, 18:19 UTC

Marktinformatie

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sep 2025, 18:01 UTC

Marktinformatie

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sep 2025, 17:34 UTC

Marktinformatie

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sep 2025, 16:53 UTC

Winsten

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sep 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 16:15 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Commodities Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Energy Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sep 2025, 15:22 UTC

Marktinformatie

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sep 2025, 15:21 UTC

Marktinformatie

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Vergelijking

Prijswijziging

Bio-Techne Corp Prognose

Koersdoel

By TipRanks

27.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 66 USD  27.86%

Hoogste 75 USD

Laagste 53 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Techne Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technische score

By Trading Central

49.67 / 50.24Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

82 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat